vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and Playboy, Inc. (PLBY). Click either name above to swap in a different company.

Playboy, Inc. is the larger business by last-quarter revenue ($34.9M vs $19.6M, roughly 1.8× STANDARD BIOTOOLS INC.). Playboy, Inc. runs the higher net margin — 10.3% vs -177.4%, a 187.7% gap on every dollar of revenue. On growth, Playboy, Inc. posted the faster year-over-year revenue change (4.2% vs -11.5%). Playboy, Inc. produced more free cash flow last quarter ($1.1M vs $-23.1M). Over the past eight quarters, Playboy, Inc.'s revenue compounded faster (11.0% CAGR vs -12.2%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Playboy is an American men's lifestyle and entertainment magazine, available both online and in print. It was founded in Chicago in 1953 by Hugh Hefner and his associates, funded in part by a $1,000 loan from Hefner's mother.

LAB vs PLBY — Head-to-Head

Bigger by revenue
PLBY
PLBY
1.8× larger
PLBY
$34.9M
$19.6M
LAB
Growing faster (revenue YoY)
PLBY
PLBY
+15.7% gap
PLBY
4.2%
-11.5%
LAB
Higher net margin
PLBY
PLBY
187.7% more per $
PLBY
10.3%
-177.4%
LAB
More free cash flow
PLBY
PLBY
$24.2M more FCF
PLBY
$1.1M
$-23.1M
LAB
Faster 2-yr revenue CAGR
PLBY
PLBY
Annualised
PLBY
11.0%
-12.2%
LAB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LAB
LAB
PLBY
PLBY
Revenue
$19.6M
$34.9M
Net Profit
$-34.7M
$3.6M
Gross Margin
48.5%
73.3%
Operating Margin
-168.5%
7.9%
Net Margin
-177.4%
10.3%
Revenue YoY
-11.5%
4.2%
Net Profit YoY
-28.8%
128.6%
EPS (diluted)
$-0.09
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
PLBY
PLBY
Q4 25
$34.9M
Q3 25
$19.6M
$29.0M
Q2 25
$21.8M
$28.1M
Q1 25
$40.8M
$28.9M
Q4 24
$33.5M
Q3 24
$22.1M
$29.4M
Q2 24
$22.5M
$24.9M
Q1 24
$45.5M
$28.3M
Net Profit
LAB
LAB
PLBY
PLBY
Q4 25
$3.6M
Q3 25
$-34.7M
$460.0K
Q2 25
$-33.5M
$-7.7M
Q1 25
$-26.0M
$-9.0M
Q4 24
$-12.5M
Q3 24
$-26.9M
$-33.8M
Q2 24
$-45.7M
$-16.7M
Q1 24
$-32.2M
$-16.4M
Gross Margin
LAB
LAB
PLBY
PLBY
Q4 25
73.3%
Q3 25
48.5%
76.0%
Q2 25
48.8%
65.4%
Q1 25
48.4%
68.6%
Q4 24
70.8%
Q3 24
54.9%
61.0%
Q2 24
46.1%
67.8%
Q1 24
53.1%
55.8%
Operating Margin
LAB
LAB
PLBY
PLBY
Q4 25
7.9%
Q3 25
-168.5%
4.7%
Q2 25
-118.1%
-20.9%
Q1 25
-80.8%
-21.7%
Q4 24
-13.3%
Q3 24
-120.9%
-96.0%
Q2 24
-134.5%
-37.0%
Q1 24
-132.2%
-31.5%
Net Margin
LAB
LAB
PLBY
PLBY
Q4 25
10.3%
Q3 25
-177.4%
1.6%
Q2 25
-153.7%
-27.3%
Q1 25
-63.8%
-31.3%
Q4 24
-37.4%
Q3 24
-122.0%
-114.7%
Q2 24
-203.3%
-66.9%
Q1 24
-70.6%
-58.1%
EPS (diluted)
LAB
LAB
PLBY
PLBY
Q4 25
$0.05
Q3 25
$-0.09
$0.00
Q2 25
$-0.09
$-0.08
Q1 25
$-0.07
$-0.10
Q4 24
$-0.13
Q3 24
$-0.07
$-0.45
Q2 24
$-0.12
$-0.23
Q1 24
$-0.27
$-0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
PLBY
PLBY
Cash + ST InvestmentsLiquidity on hand
$129.4M
$37.8M
Total DebtLower is stronger
$174.2M
Stockholders' EquityBook value
$399.7M
$18.4M
Total Assets
$539.6M
$292.4M
Debt / EquityLower = less leverage
9.48×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
PLBY
PLBY
Q4 25
$37.8M
Q3 25
$129.4M
$27.5M
Q2 25
$158.6M
$19.6M
Q1 25
$150.9M
$23.7M
Q4 24
$30.9M
Q3 24
$210.6M
$9.5M
Q2 24
$269.8M
$16.9M
Q1 24
$287.1M
$19.0M
Total Debt
LAB
LAB
PLBY
PLBY
Q4 25
$174.2M
Q3 25
$176.8M
Q2 25
$177.5M
Q1 25
$176.3M
Q4 24
$176.6M
Q3 24
$55.2M
$200.0M
Q2 24
$55.1M
$196.3M
Q1 24
$55.0M
$193.4M
Stockholders' Equity
LAB
LAB
PLBY
PLBY
Q4 25
$18.4M
Q3 25
$399.7M
$3.8M
Q2 25
$424.5M
$-17.5M
Q1 25
$454.6M
$-11.4M
Q4 24
$-7.7M
Q3 24
$489.3M
$-15.7M
Q2 24
$510.3M
$15.7M
Q1 24
$577.3M
$29.5M
Total Assets
LAB
LAB
PLBY
PLBY
Q4 25
$292.4M
Q3 25
$539.6M
$278.3M
Q2 25
$557.0M
$264.1M
Q1 25
$579.6M
$270.6M
Q4 24
$284.7M
Q3 24
$681.5M
$271.5M
Q2 24
$708.7M
$301.8M
Q1 24
$777.7M
$309.1M
Debt / Equity
LAB
LAB
PLBY
PLBY
Q4 25
9.48×
Q3 25
46.86×
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
12.51×
Q1 24
0.10×
6.54×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
PLBY
PLBY
Operating Cash FlowLast quarter
$-22.2M
$1.4M
Free Cash FlowOCF − Capex
$-23.1M
$1.1M
FCF MarginFCF / Revenue
-118.1%
3.2%
Capex IntensityCapex / Revenue
4.5%
0.8%
Cash ConversionOCF / Net Profit
0.39×
TTM Free Cash FlowTrailing 4 quarters
$-111.1M
$-1.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
PLBY
PLBY
Q4 25
$1.4M
Q3 25
$-22.2M
$10.1M
Q2 25
$-20.7M
$-3.9M
Q1 25
$-30.3M
$-7.6M
Q4 24
$161.0K
Q3 24
$-27.9M
$-6.5M
Q2 24
$-39.0M
$-3.0M
Q1 24
$-62.5M
$-9.8M
Free Cash Flow
LAB
LAB
PLBY
PLBY
Q4 25
$1.1M
Q3 25
$-23.1M
$9.8M
Q2 25
$-22.6M
$-4.3M
Q1 25
$-35.3M
$-7.7M
Q4 24
$-401.0K
Q3 24
$-30.1M
$-7.0M
Q2 24
$-41.0M
$-3.7M
Q1 24
$-63.3M
$-10.3M
FCF Margin
LAB
LAB
PLBY
PLBY
Q4 25
3.2%
Q3 25
-118.1%
33.8%
Q2 25
-103.6%
-15.2%
Q1 25
-86.6%
-26.5%
Q4 24
-1.2%
Q3 24
-136.4%
-23.7%
Q2 24
-182.2%
-14.8%
Q1 24
-138.9%
-36.5%
Capex Intensity
LAB
LAB
PLBY
PLBY
Q4 25
0.8%
Q3 25
4.5%
1.1%
Q2 25
8.7%
1.4%
Q1 25
12.4%
0.1%
Q4 24
1.7%
Q3 24
10.2%
1.5%
Q2 24
8.6%
2.6%
Q1 24
1.7%
2.1%
Cash Conversion
LAB
LAB
PLBY
PLBY
Q4 25
0.39×
Q3 25
22.02×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

PLBY
PLBY

Transferred At Point In Time$22.2M64%
Trademark Licensing$6.5M19%
Related Party$5.0M14%
Other$1.1M3%

Related Comparisons